6712 Journal of Medicinal Chemistry, 2005, Vol. 48, No. 21
Coppola et al.
(22) Lebovitz, H. E. R-Glucosidase Inhibitors. Endocrin. Metabol.
Clin. North Amer. 1997, 26, 539-551.
(23) Treadway, J. L.; Mendys, P.; Hoover, D. J. Glycogen Phosphoryl-
ase Inhibitors for Treatment of Type 2 Diabetes Mellitus. Exp.
Opin. Invest. Drugs 2001, 10, 439-454.
(24) (a) Barf, T. Intervention of Hepatic Glucose Production. Small
Molecule Regulators of Potential Targets for Type 2 Diabetes
Therapy. Mini-Reviews in Medicinal Chemistry 2004, 4, 897-
908. (b) Fotsch, C.; Askew, B. C.; Jian, J. 11â-Hydroxysteroid
Dehydrogenase-1 as a Therapeutic Target for Metabolic Dis-
eases. Expert Opin. Ther. Pat. 2005, 15, 289-303.
(25) (a) Krozowski, Z. 11â-Hydroxysteroid Dehydrogenase and the
Short-chain Alcohol Dehydrogenase (SCAD) Superfamily. Mol.
Cell. Endocrin. 1992, 84, C25-C31. (b) Stewart, P. M.; Whor-
wood, C. B.; Walker, B. R. Steroid Hormones and Hyperten-
sion: The Cortisol-Cortisone Shuttle. Steroids 1993, 58, 614-
620.
(26) Andrews, R. C.; Walker, B. R. Glucocorticoids and Insulin
Resistance: Old Hormones, New Targets. Clin. Sci. 1999, 96,
513-523.
(27) Wajchenberg, B. L. Subcutaneous and Visceral Adipose Tissue:
Their Relation to the Metabolic Syndrome. Endocr. Rev. 2000,
21, 697-738.
(28) Kotelevtsev, Y.; Seckl, J. R.; Mullins, J. 11â-Hydroxysteroid
Dehydrogenases: Key Modulators of Glucocorticoid Action In
Vivo. Curr. Opin. Endocrinol. Diabetes 1999, 6, 191-198.
(29) Krozowski, Z.; Li, K. X. Z.; Koyama, K.; Smith, R. E.;
Obeyesekere, V. R.; Stein-Oakley, A.; Sasano, H.; Coulter, C.;
Cole, T.; Sheppard, K. E. The Type I and Type II 11â-Hydroxy-
steroid Dehydrogenase Enzymes. J. Steroid Biochem. Mol. Biol.
1999, 69, 391-401.
(30) Edwards, C. R.; Benediktsson, R.; Lindsay, R. S.; Seckl, J. R.
11â-Hydroxysteroid Dehydrogenases: Key Enzymes in Deter-
mining Tissue-specific Glucocorticoid Effects. Steroids 1996, 61,
263-269.
(45) Pinder, R. M.; Brogden, R. N.; Sawyer, P. R.; Speight, T. M.;
Spencer, R.; Avery, G. S. Carbenoxolone: A Review of its
Pharmacological Properties and Therapeutic Efficacy in Peptic
Ulcer Disease. Drugs 1976, 11, 245-307.
(46) Pindado, S.; Corrigan, O.; O’Driscoll, C. M. Carbenoxolone
Sodium. Anal. Profiles Drug Subst. Excipients 1996, 24, 1-43.
(47) Nakamura, Y. Carbenoxolone and its Sodium Salt. Japanese
Patent 61165348 1986; Chem. Abstr. 106, 5278.
(48) Martinez, R.; Arellano-Garcia, M.; Martinez-Vazquez, M.;
Gallegos, J. A. Synthesis of Carbenoxolone Analogues From
Argentatin B. Org. Prep. Proced. Int. 1993, 25, 698-703.
(49) Peng, Y.; Han, Y.; Wang, C.; Feng, R. Synthesis of Carbenoxolone
Sodium. Zhongguo Yiyao Gongye Zazhi 1994, 25, 106-107;
Chem. Abstr. 121, 109395.
(50) Monder, C.; Stewart, P. M.; Lakshmi, V.; Valentino, R.; Burt,
D.; Edwards, C. R. W. Licorice Inhibits Corticosteroid 11â-
Dehydrogenase of Rat Kidney and Liver: In Vivo and In Vitro
Studies. Endocrinol. 1989, 125, 1046-1053.
(51) Buhler, H.; Perschel, F. H.; Hierholzer, K. Inhibition of Rat Renal
11â-hydroxysteroid Dehydrogenase by Steroidal Compounds and
Triterpenoids: Structure/Function Relationship. Biochim. Bio-
phys. Acta 1991, 1075, 206-212.
(52) Diederich, S.; Grossmann, C.; Hanke, B.; Quinkler, M.; Herr-
mann, M.; Ba¨hr, V.; Oelkers, W. In the Search for Specific
Inhibitors of Human 11â-Hydroxysteroid-dehydrogenases (11â-
HSDs): Chenodeoxycholic Acid Selectively Inhibits 11â-HSD-I.
Eur. J. Endocrin. 2000, 142, 200-207.
(53) Barf, T.; Vallgarda, J.; Emond, R.; Ha¨ggstro¨m, C.; Kurz, G.;
Nygren, A.; Larwood, V.; Mosialou, E.; Axelsson, K.; Olsson, R.;
Engblom, L.; Edling, N.; Ro¨nquist-Nii, Y.; O¨ hman, B.; Alberts,
P.; Abrahmsen, L. Arylsulfonamidothiazoles as a New Class of
Potential Antidiabetic Drugs. Discovery of Potent and Selective
Inhibitors of the 11â-Hydroxysteroid Dehydrogenase Type 1. J.
Med. Chem. 2002, 45, 3813.
(54) In the initial phases of this program compounds were screened
using pig liver 11â-HSD1 due to the large amounts of enzyme
required for the high-capacity screening and preliminary multi-
parallel synthetic efforts. We subsequently replaced the porcine
enzyme with the more relevant human 11â-HSD1 and found that
the class of compounds described in this paper tended to be much
less active (e.g. the IC50 for 5 is 128 µM). In addition, the IC50’s
of 106 compounds of different structural classes were compared
in both pig and human enzymes and there was little correlation
between them. Consequently, all 11â-HSD1 data reported in this
paper is based on the human enzyme.
(55) Bettoni, G.; Franchini, C.; Perrone, R.; Tortorella, V. Synthesis
and Absolute Configuration of Substituted Morpholines Tetra-
hedron 1980, 36, 409-415.
(56) Some compounds were screened for HSD2 prior to setting the
selection criteria, therefore a few HSD1 values of >1 µM are
reported.
(57) Pilkis, S. J.; Granner, D. K. Molecular Physiology of the
Regulation of Hepatic Gluconeogenesis and Glycolysis. Annu.
Rev. Physiol. 1992, 54, 888-909.
(58) Consoli, A.; Nurjhan, N.; Capani, F.; Gerich, J. Predominant Role
of Gluconeogenisis in Increased Hepatic Glucose Production in
NIDDM. Diabetes 1989, 38, 550-557.
(59) Still, W. C.; Kahn, M.; Mitra, A. Rapid Chromatographic
Technique for Preparative Separations with Moderate Resolu-
tion. J. Org. Chem. 1978, 43, 2923-2925.
(60) Tommasi, R. A.; Whaley, L. W.; Marepalli, H. R. Autochem:
Automated Solution-Phase Oarallel Synthesis and Purification
via HPLC. J. Comb. Chem. 2000, 2, 447-449.
(31) Seckl, J. R.; Walker, B. R. Minireview: 11â-Hydroxysteroid
Dehydrogenase Type 1 - A Tissue-Specific Amplifier of Gluco-
corticoid Action. Endocrinology 2001, 142, 1371-1376.
(32) Sandeep, T. C.; Walker, B. R. Pathophysiology of Modulation of
Local Glucocorticoid Levels by 11â-Hydroxysteroid Dehydro-
genases. Trends Endocrinol. Metab. 2001, 12, 446-453.
(33) Walker, B. R.; Connacher, A. A.; Lindsay, R. M.; Webb, D. J.;
Edwards, C. R. W. Carbenoxolone Increases Hepatic Insulin
Sensitivity in Man: A Novel Role for 11-Oxosteroid Reductase
in Enhancing Glucocorticoid Receptor Activation. J. Clin. En-
dicrinol. Metab. 1995, 80, 3155-3159.
(34) Hult, M.; Jornvall, H.; Oppermann, U. C. T. Selective Inhibition
of Human Type 1 11â-Hydroxysteroid Dehydrogenase by Syn-
thetic Steroids and Xenobiotics. FEBS Lett. 1998, 441, 25-28.
(35) Kotelevtsev, Y.; Holmes, M. C.; Burchell, A.; Houston, P. M.;
Schmoll, D.; Jamieson, P.; Best, R.; Brown, R.; Edwards, C. R.
W.; Seckl, J. R.; Mullins, J. J. 11â-Hydroxysteroid Dehydro-
genase Type 1 Knockout Mice Show Attenuated Glucocorticoid-
inducible Responses and Resist Hyperglycemia on Obesity or
Stress. Proc. Nat. Acad. Sci. U.S.A. 1997, 94, 14924-14929.
(36) Wilson, R. C.; Krozowski, Z. S.; Lee, K.; Obeyesekere, V. R.;
Razzaghy-Azar, M.; Harbison, M. D.; Wei, J. Q.; Shackleton, C.
H. L.; Funder, J. W.; New, M. I. A Mutation in the HSD11â2
Gene in a Family with Apparent Mineralocorticoid Excess. J.
Clin. Endocrinol. Metab. 1995, 80, 2263-2266.
(37) Mune, T.; Rogerson, F. M.; Nikkila, H.; Agarwal, A. K.; White,
P. C. Human Hypertension Caused by Mutations in the Kidney
Isozyme of 11â-Hydroxysteroid Dehydrogenase. Nat. Genet.
1995, 10, 394-399.
(38) Stewart, P. M.; Krozowski, Z. S.; Gupta, A.; Milford, D. V.; Howie,
A. J.; Sheppard, M. C.; Whorwood, C. B. Hypertension in the
Syndrome of Apparent Mineralocorticoid Excess Due to Mutation
of the 11â-Hydroxysteroid Dehydrogenase Type 2 Gene. Lancet
1996, 347, 88-91.
(39) Li, K. X. Z.; Obeyesekere, V. R.; Zygmunt, S.; Ferrari, P.
Oxoreductase and Dehydrogenase Activities ot the Human and
Rat 11â-Hydroxysteroid Dehydrogenase Type 2 Enzyme. Endo-
crinology 1997, 138, 2948-2952.
(40) Stewart, P. M. Cortisol as a Mineralocorticoid in Human Disease.
J. Steroid Biochem. Mol. Biol. 1999, 69, 403-408.
(61) Varma, R. S.; Kapoor, A. 1-(4′-Benzazolylmethylaminobenzoyl)-
morpholines and Piperidines as Antimicrobial Agents. Ind. J.
Chem. 1979, 18B, 200-202.
(62) Kruse, C. H.; Holden, K. G.; Pritchard, M. L.; Field, J. A.;
Rieman, D. J.; Greig, R. G.; Poste, G. Synthesis and Evaluation
of Multisubstrate Inhibitors of an Oncogene-Encoded Tyrosine-
Specific Protein Kinase. 1. J. Med. Chem. 1988, 31, 1762-1767.
(63) Munakata, K.; Tanaka, S.; Toyoshima, S. Therapy for Uro-
lithiasis with Hydroxamic Acids. I. Synthesis of New N-(Aroyl)-
glycinohydroxamic Acid Derivatives and Related Compounds.
Chem. Pharm. Bull. 1980, 28, 2045-2051.
(64) Leuck, G. J.; Perkins, R. P.; Whitmore, F. C. The Mercuration
of Naphthalic Acids. J. Am. Chem. Soc. 1929, 51, 1831-1836.
(65) Dunbar, P. G.; Durant, G. J.; Hoss, W. P.; Messer, W. S., Jr.
Preparation of Pyridine and Pyrimidine Derivatives as Musca-
rinic Agents. US Patent 1992, 5, 175, 166; Chem. Abstr. 118,
139862.
(41) Murav’ev, I. A. Chemical Composition and Technology of Licorice
and its Preparations. Farm. Pol. 1967, 23, 559-566; Chem.
Abstr. 68:117104.
(42) Murav’ev, I. A.; Savchenko, L. N. Preparation of Glycyrrhetinic
Acid from Licorice Root Extracts. Khim.-Farm. Zh. 1979, 13, 97-
102; Chem. Abstr. 91, 71699.
(43) Sobotka-Wierzbowicz, J.; Adamczyk, H.; Smulkowska, H. Den-
sitometric Determination of Glycyrrhizic Acid in Dried Licorice
Extract. Farm. Pol. 1984, 40, 527-529; Chem. Abstr. 103, 3762.
(44) Tsai, T.; Chen, C. Determination of Three Active Principles in
Licorice Extract by Reverse-phase High-performance Liquid
Chromatography. J. Chromatog. 1991, 542, 521-525.
(66) Bettoni, G.; Franchini, C.; Perrone, R.; Tortorella, V. Synthesis
and Absolute Configuration of Substituted Morpholines. Tetra-
hedron 1980, 36, 409-415.
JM058228Q